[Ip-health] Gilead Remdesivir Licenses: Half measures are not nearly good enough

Joel Lexchin joel.lexchin at utoronto.ca
Tue May 12 19:15:46 PDT 2020

Hi Brook:

I have no argument with what you said about Gilead and the way its approaching access to remdesivir. However, I’m wondering about whether it might be better to wait for the peer reviewed publication of the remdesivir study before advocating that countries start to issue compulsory licenses. It might turn out to be less effective than the preliminary analysis indicated in which case countries could have used up valuable resources on something that is not that useful.


Joel Lexchin MD
Associate Professor
Department of Family and Community Medicine
University of Toronto
E mail:	joel.lexchin at utoronto.ca	

More information about the Ip-health mailing list